Callisto Reports Status of Atiprimod Trial in Relapsed Multiple Myeloma

Callisto Pharmaceuticals has announced the interim status of its Phase I/IIa trial with Atiprimod in patients with multiple myeloma.

The trial, titled "An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Refractory or Relapsed Multiple Myeloma," is currently underway at four clinical sites in the U.S. Three patient cohorts have now completed dosing at 30 mg, 60 mg and 90 mg, and a fourth dosing cohort is currently underway at 120 mg.

No dose-limiting toxicities have been observed to date. A fifth dose cohort at 180 mg is anticipated to begin in the next six to eight weeks. No additional clinical sites are anticipated for this trial, as a pronounced increase in patient accrual has occurred in the past few months.